● Recruiting

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

Condition: PARKINSON DISEASE (Disorder) · Sponsor: University Hospital Tuebingen

PhasePhase 3

Planned participants150

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study is a Phase III multicentric randomized controlled trial with parallel group design and waiting list in patients that have an indication to undergo intestinal L-Dopa + entacapone (Lecigon®) under the existing indication criteria (according to SmPC (Fachinformation) Lecigon®). As primary endpoint, we will analyze the difference of the pre-interventional baseline and 6-month follow-up on the "hyperdopaminergic symptoms" corresponding to section 3 of the "Ardouin Behavioural Scale" hypothesizing on the superiority of LECIG therapy compared to best medical treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Daniel Weiss, Prof · 0049 (0) 7071-29-82340 · Daniel.weiss@uni-tuebingen.de

Always discuss trial participation with your own doctor first.

Locations (7)

DRK gemeinnützige Krankenhausgesellschaft mbH Saarland	Saarlouis, Saarland, Germany	Recruiting
Charité Campus Mitte	Berlin, Germany	Recruiting
Knappschaft Kliniken Bottrop GmbH	Bottrop, Germany	Not Yet Recruiting
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR	Dresden, Germany	Recruiting
University Hospital Marburg	Marburg, Germany	Not Yet Recruiting
Centre for Neurology, Department forNeurodegenerative Disease, and Hertie-Institute forClinical Brain Research	Tübingen, Germany	Recruiting
Parkinson-Klinik Ortenau GmbH & Co. KG	Wolfach, Germany	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07151378